W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 14.46 CNY -5.61% Market Closed
Market Cap: 23.1B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note

Walvax Biotechnology Co Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Walvax Biotechnology Co Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
W
Walvax Biotechnology Co Ltd
SZSE:300142
Selling, General & Administrative
-ÂĄ1.5B
CAGR 3-Years
3%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
Beigene Ltd
HKEX:6160
Selling, General & Administrative
-ÂĄ10.9B
CAGR 3-Years
-38%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Selling, General & Administrative
-ÂĄ1.9B
CAGR 3-Years
-32%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Selling, General & Administrative
-ÂĄ781.3m
CAGR 3-Years
-11%
CAGR 5-Years
-3%
CAGR 10-Years
-17%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Selling, General & Administrative
-ÂĄ3.5B
CAGR 3-Years
-25%
CAGR 5-Years
-26%
CAGR 10-Years
-28%
Imeik Technology Development Co Ltd
SZSE:300896
Selling, General & Administrative
-ÂĄ397.2m
CAGR 3-Years
-51%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
No Stocks Found

Walvax Biotechnology Co Ltd
Glance View

Market Cap
23.2B CNY
Industry
Biotechnology

Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.

Intrinsic Value
15.56 CNY
Undervaluation 7%
Intrinsic Value
Price
W

See Also

What is Walvax Biotechnology Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-1.5B CNY

Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Selling, General & Administrative amounts to -1.5B CNY.

What is Walvax Biotechnology Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-14%

Over the last year, the Selling, General & Administrative growth was 34%. The average annual Selling, General & Administrative growth rates for Walvax Biotechnology Co Ltd have been 3% over the past three years , -25% over the past five years , and -14% over the past ten years .

Back to Top